Newsletter  |  October 2014  
REDEFINING QUALITY - Full Service Provider Focused on Early Stage Clinical Research

Development and Validation of an ELISA for the Determination of
AB-16B5 in Rat Serum

On October 21 and 22, join Robert Massé, Vice President, Large Molecule Bioanalysis, Algorithme Pharma, and Alethia Biotherapeutics, at the Bioassays and Bioanalytical Method Development Meeting, in Boston, as they present a poster on the approach used for method development and the fit-for-purpose validation scheme of an enzyme-linked immunosorbent assay (ELISA) designed to quantitate AB-16B5 in rat serum and assess its stability parameters using incurred samples.

For more details or to request a poster reprint >>

AAPS Annual Meeting, San Diego

On Wednesday, November 5, from 8:30 a.m. to
11 a.m., Dr. Fabio Garofolo, Vice President, Bioanalytical Services, Algorithme Pharma, will be hosting a session entitled 'Conclusions from the Global Bioanalytical Consortium: Chromatographic-Related Bioanalytical Science is Universal!'.

We look forward to seeing you at booth #2741 and hope you will join us for our 22 poster presentations.

For more details or to request poster reprints >>

Webinar — Impaired Renal Function Clinical Trials: Early Phase Planning to Minimize Risks and Accelerate Drug Development

This webinar presents a clinical trial case study in patients with impaired renal function to examine the impact of four renal impairment stage levels on an investigational drug's pharmacokinetic and safety characteristics. With Algorithme Pharma's optimal study design, we were able to accelerate our sponsor's project timelines by 3 to 5 months, from writing the protocol to completing the clinical trial. The key was to incorporate patients effectively and efficiently, while preserving result integrity and patient safety.

Renal Impairment Microsite

7th Open Symposium of EBF

On Wednesday, November 19, beginning at
11:40 a.m., Dr. Fabio Garofolo will be presenting, "Recent Trends in Antibody-Drug Conjugate (ADC) Bioanalysis: Total Antibody Quantification by HRMS."

Our six Poster Presentations will include:


Strategies to Eliminate Anti-Drug Antibody (ADA) Interference due to Immunogenicity on Large Molecule Quantification by LC-MS/MS



Request more information >>

Application and Advantages of HRMS in the Quantification of Therapeutic Monoclonal Antibodies: "The Rituximab Case Study"



Request more information >>

The 505(b)(2) Forum - Logo

Exploring the Pathway of Product Development Success

You’re invited to an exclusive complimentary dinner and presentation held at the GPhA Fall Technical Conference by the 505(b)(2) Forum, where Marc Lefebvre, Vice-President, Scientific Affairs, Algorithme Pharma, will present Understanding drug-drug interaction in product development.

To register >>

Customizable First-In-Human Trial Gantt Chart

We designed our First-In-Human (FIH) Trial Web App to help in the planning of early stage clinical timelines.

Gantt Chart thumbnail
Try the tool >>

Request to
Meet Us

Bioassays and Bioanalytical Development Meeting

October 20-22
Boston, MA


GPhA Fall Technical Conference 2014

October 27-29
Bethesda, MD


DIA's 2014 Annual Canadian Meeting

October 28-29
Ottawa, ON


AAPS 2014 Annual Meeting

November 2-6
San Diego, CA

Visit us at booth# 2741


Bioequivalence: Intersection Between Science and Regulatory

November 5-6
San Diego, CA


EBF European Bioanalysis Forum 2014

November 19-21
Barcelona, Spain

For more information, please contact us:
450 973-6077 | 888 267-7449 | contact@algopharm.com
©2014 All Rights Reserved, Algorithme Pharma inc., 2014